East Midlands Airport rules for baggage drop off and what you can't take on a plane It is important to check the details Nottingham Post · Jul 19, 2022
Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller Benzinga · Jul 15, 2022
East Midlands Airport update on summer holiday check in times They are keen to minimise delays Nottingham Post · Jul 13, 2022
InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19 InflaRx N.V. (NASDAQ:IFRX) provided a development update for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19. The FDA and the European Medicines Agency (EMA) have granted orphan drug designation to vilobelimab for PG. PG is a rare condition that causes large, painful sores (ulcers) to develop on the skin.… Benzinga · Jun 29, 2022
Adverum Biotech Receives EMA's Priority Medicines Status For Chronic Eye Disorder Candidate The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ (NASDAQ: ADVM) lead drug ADVM-022 for the treatment of wet age-related macular degeneration (wet AMD). Benzinga · Jun 24, 2022
BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug BioNTech (NASDAQ: BNTX) received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its product candidate BNT211 in the third- or later-line treatment of testicular germ cell tumors. Benzinga · Jun 23, 2022
EU regulator authorizes COVID shot made by France's Valneva The European Medicines Agency says it is recommending the authorization of the coronavirus vaccine made by French pharmaceutical Valneva, making it the sixth shot to be given the green light in Europe The Independent UK · Jun 23, 2022
Nasr to make Spa 24 Hours debut in EMA Porsche Ex-Formula 1 driver Felipe Nasr will make his Spa 24 Hours debut next month as part of an all-factory driver line-up in a Porsche fielded by Australian entrant EMA Motorsport. Motorsport · Jun 20, 2022
Ex-F1 driver Nasr to make Spa 24 Hours debut in EMA Porsche Ex-Formula 1 driver Felipe Nasr will make his Spa 24 Hours debut next month as part of an all-factory driver line-up in a Porsche fielded by Australian entrant EMA Motorsport. Autosport · Jun 20, 2022
Legend Biotech Shares Move Higher After Bullish BMO Pitch BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy Though the analyst expects a gradual increase in sales due… Benzinga · Jun 17, 2022
East Midlands Airport announces summer changes to deal with huge number of passengers “We want our passengers to have the best possible start to their trips and holidays" Nottingham Post · Jun 15, 2022
East Midlands Airport joint statement after flights divert over 'drone sightings' at Download Police patrols have increased Nottingham Post · Jun 10, 2022
Giant fungus spreading into rivers near East Midlands Airport being investigated Concerns have been raised about the impact of the process Nottingham Post · Jun 9, 2022
Thousands sign petition demanding 35 kids with Cystic Fibrosis be given life-saving drug Kaftrio 'The lives of our children are at stake here, and we need to have this drug' Irish Mirror · Jun 2, 2022
Benzinga · May 19, 2022 The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · May 18, 2022 Tetra Bio-Pharma Receives EMA Orphan Drug Designation For A Novel Topical Therapeutic Containing CBD The European Medicines Agency (EMA) has classified Tetra Bio-Pharma Inc.’s (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB).
Benzinga · May 16, 2022 Why Valneva's Shares Are Plunging Today Premarket Valneva SE (NASDAQ:VALN) warned it might have to reconsider its FY22 financial guidance after the European Commission informed the company of its intent to terminate an advance purchase agreement (APA) for its VLA2001 COVID-19 candidate vaccine. In November, the company signed the APA with the European Commission to supply up to 60 million doses of…
Nottingham Post · May 10, 2022 East Midlands Airport statement as 3000 passengers affected by incident Flights were also delayed
Benzinga · Apr 28, 2022 Dupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance Sanofi SA (NASDAQ:SNY) posted a net profit of €2 billion for Q1 FY22, up from €1.57 billion a year ago. Sales reached €9.67 billion, up from €8.59 billion in Q1 FY21. Eczema drug, Dupixent, and consumer healthcare drove the growth. Dupixent alone grew by 45.7% to €1.6 billion, driving Sanofi's specialty care…
Benzinga · Apr 27, 2022 Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…
Benzinga · Apr 21, 2022 AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo. There were no…
Benzinga · Apr 14, 2022 Valneva Shares Jump As Its COVID-19 Vaccine Receives Conditional Approved In UK The Healthcare products Regulatory Agency (MHRA) of the U.K. has granted Conditional Marketing Authorization for Valneva SE's (NASDAQ:VALN)COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age. MHRA found that VLA2001 meets safety, quality, and effectiveness standards. This new marketing authorization comes in addition to the emergency use authorization,…
Benzinga · Apr 13, 2022 ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce ProQR Therapeutics N.V. (NASDAQ:PRQR) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform. The Company will suspend the development of QR-1123 for autosomal dominant retinitis pigmentosa, QR-504a for Fuchs endothelial corneal dystrophy, and all other Inherited Retinal diseases (IRD)-related research activities. ProQR will implement…
Benzinga · Apr 7, 2022 Europe Holds Second COVID-19 Booster Dose For People Aged Under 80 Years European Medicines Agency concluded that it is too early to consider using the fourth dose of either Pfizer Inc (NYSE:
Nottingham Post · Apr 7, 2022 East Midlands Airport set for 'busiest weekend since Covid restrictions were lifted' It said it is putting in plans to cope with the extra demand